Why AbbVie Stock Jumped Today

Impact · against what's priced in

AbbVie's $10.9 billion acquisition of Apogee Therapeutics provides a long-term strategic hedge against the eventual decline of its current immunology blockbusters, though earnings contributions are deferred until 2032. For Apogee, the deal provides an immediate and significant valuation step-up via a 49% acquisition premium.

APGE+1.00

No priced-in read yet

In context

The company is being acquired by AbbVie in an all-cash deal at $135.11 per share, representing a 49% premium over its last closing price.

Read from the article alone

• immunology▲200%
• healthcare
• biotech
• m and a
• ABBV
• APGE
• acquisition
• clinical stage
• pharma